Stay updated on Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The clinical trial record is available, including the study design and treatments, eligibility criteria, outcome measures, recruitment status, locations, publications, and study documents.
    Difference
    100%
    Check dated 2026-11-07T11:31:08.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer now shows revision v3.8.0 instead of v3.7.2. The study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T10:53:15.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide notice announces a transition from the term “Artificial Intelligence” to “Super Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-24T11:58:57.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-17T13:47:24.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error, with the displayed site revision updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T13:47:26.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page instead of the study record content, indicating access denial to the resource. The layout mirrors the site chrome with header and footer, but no study data is rendered.
    Difference
    0.5%
    Check dated 2026-09-26T17:24:11.000Z thumbnail image

Stay in the know with updates to Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.